Walgreens (NYSE: WAG) (Nasdaq: WAG) had March sales of $6.16 billion, an
increase of 2.3 percent from $6.02 billion for the same month in fiscal
2012.
Total front-end sales increased 5.4 percent compared with the same month
in fiscal 2012, while comparable store front-end sales increased 4.2
percent. Customer traffic in comparable stores decreased 1.3 percent
while basket size increased 5.5 percent.
Prescriptions filled at comparable stores increased by 4.0 percent in
March and increased 7.4 percent on a calendar day-shift adjusted basis.
This year’s March had one additional Sunday and one fewer Thursday
compared with March 2012. In addition, Easter fell on March 31 this year
compared with April 8 last year. These calendar shifts negatively
impacted prescriptions filled at comparable stores by 3.4 percentage
points.
The company said the percentage of former Express Scripts customers
returning to its pharmacies continued to increase in March.
March pharmacy sales increased by 0.4 percent, while comparable store
pharmacy sales decreased 1.5 percent but increased by a calendar
day-shift adjusted 1.9 percent. Calendar day shifts negatively impacted
pharmacy sales in comparable stores by 3.4 percentage points. Calendar
day-shift adjusted comparable store pharmacy sales were negatively
impacted by 4.8 percentage points due to generic drug introductions in
the last 12 months. Pharmacy sales accounted for 62.2 percent of total
sales for the month.
Sales in comparable stores increased by 0.7 percent in March. Calendar
day shifts negatively impacted total comparable sales by 2.1 percentage
points, while generic drug introductions in the last 12 months
negatively impacted total comparable sales by 3.0 percentage points.
The company will report combined comparable store sales for March and
April with its April sales results.
Registrations for Walgreens Balance® Rewards loyalty program,
which launched in September, totaled more than 64 million through March.
Calendar 2013 sales to date were $18.09 billion, an increase of 2.3
percent from $17.68 billion in 2012.
Fiscal 2013 year-to-date sales for the first seven months were $42.12
billion, down 1.7 percent from $42.83 billion in the comparable period
in fiscal 2012.
Walgreens opened 12 stores during March, including four relocations, and
closed one.
On March 31, Walgreens operated 8,541 locations in all 50 states, the
District of Columbia, Puerto Rico and Guam. That includes 8,077
drugstores, 230 more than a year ago, including 101 net stores acquired
over the last 12 months. The company also operates infusion and
respiratory services facilities, specialty pharmacies and mail service
facilities. Its Take Care Health Systems subsidiary manages more than
700 in-store convenient care clinics and worksite health and wellness
centers.
March Comparable Sales and Prescriptions Filled
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cough,
|
|
|
|
|
Calendar
|
|
Generics
|
|
Cold, Flu
|
|
|
Actual
|
|
Shift Impact
|
|
Impact
|
|
Impact
|
|
|
|
|
|
|
|
|
|
Total Comp Sales
|
|
0.7%
|
|
-2.1%
|
|
-3.0%
|
|
0.0%
|
|
|
|
|
|
|
|
|
|
Comp Front End
|
|
4.2%
|
|
-
|
|
-
|
|
-
|
|
|
|
|
|
|
|
|
|
Comp Rx Sales
|
|
-1.5%
|
|
-3.4%
|
|
-4.8%
|
|
0.0%
|
|
|
|
|
|
|
|
|
|
Comp Rx Scripts
|
|
4.0%*
|
|
-3.4%
|
|
-
|
|
0.0%
|
* Includes +1.8 percentage point from patients filling more 90-day
prescriptions
Please note: Sales numbers and the adjustments shown in the table are
preliminary, unaudited and subject to revision. Comparable stores are
defined as those drugstore locations open for at least 12 consecutive
months without closure for seven or more consecutive days and without a
major remodel or a natural disaster in the past 12 months. Acquired
operating locations and relocations are not included as comparable
stores for the first 12 months after the acquisition or relocation.
Cautionary Note Regarding Forward-Looking Statements: Statements
in this release that are not historical are forward-looking statements
made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Words such as "expect," “likely,”
"outlook," “forecast,” "would," "could," "should," “can,” “will,”
"project," "intend," "plan," "goal,” “target,” “continue," "sustain,"
“synergy,” "on track," "believe," "seek," "estimate," "anticipate,"
"may," “possible,” "assume," and variations of such words and similar
expressions are intended to identify such forward-looking statements.
These forward-looking statements are not guarantees of future
performance and involve risks, assumptions and uncertainties, including,
but not limited to, those described in Item 1A (Risk Factors) of our
most recent Annual Report on Form 10-K and Quarterly Report on Form
10-Q, each of which is incorporated herein by reference, and in other
documents that we file or furnish with the Securities and Exchange
Commission. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual
results may vary materially from those indicated or anticipated by such
forward-looking statements. Accordingly, you are cautioned not to place
undue reliance on these forward-looking statements, which speak only as
of the date they are made. Except to the extent required by law,
Walgreens does not undertake, and expressly disclaims, any duty or
obligation to update publicly any forward-looking statement after the
date of this report, whether as a result of new information, future
events, changes in assumptions or otherwise.